Tag: Zacks.com

Posted on

AstraZeneca’s Severe Asthma Drug Positive in Phase III – Zacks.com


Wall Street Journal

AstraZeneca's Severe Asthma Drug Positive in Phase III
Zacks.com
These randomized, double-blind, parallel-group, placebo-controlled studies evaluated the safety and efficacy of benralizumab as an add-on therapy in the treatment of severe uncontrolled asthma with eosinophilic inflammation in patients aged 12 years …
AstraZeneca's Asthma Drug Shows Positive ResultsWall Street Journal
AstraZeneca set to go head to head against GSK with asthma drugFinancial Times
AstraZeneca asthma drug hits goal, to enter competitive marketReuters
FierceBiotech –The Guardian –Philadelphia Business Journal
all 34 news articles »

View full post on asthma – Google News

Posted on

Glaxos Eosinophilic Asthma Drug Nucala Wins CHMP Backing – Zacks.com


BioPharma Dive

Glaxos Eosinophilic Asthma Drug Nucala Wins CHMP Backing
Zacks.com
In the U.S., the drug is approved for both COPD and asthma. We note that Glaxo has a collaboration agreement with Theravance for Relvar/Breo Ellipta and Anoro Ellipta (COPD). Relvar/Breo Ellipta generated sales of £94 million in the first half of 2015.
After bad news on Breo, Glaxo's monthly asthma drug wins an EU recBioPharma Dive

all 2 news articles »

View full post on asthma – Google News

Posted on

Theravance/Glaxos Asthma Drug Under FDA Panel Review – Zacks.com

Theravance/Glaxos Asthma Drug Under FDA Panel Review
Zacks.com
We note that Theravance and partner GlaxoSmithKline (GSK – Analyst Report) are seeking to expand the label of Breo Ellipta in the U.S. for the once-daily treatment of asthma in patients aged 12 years and above. A final response from the FDA is expected …
FDA advisory committee to review Theravance's BREO ELLIPTA (FF/VI) for asthmaPharmaceutical Business Review

all 17 news articles »

View full post on asthma – Google News

Posted on

KaloBios to Stop KB003 Development for Asthma – Zacks.com

KaloBios to Stop KB003 Development for Asthma
Zacks.com
KaloBios Pharmaceuticals, Inc. (KBIO – Snapshot Report) announced disappointing top line results from a phase II study on KB003 in patients suffering from severe asthma, where the candidate failed to meet the key endpoints. We expect the news to have a …
KaloBios calls it quits on its asthma drug after a Phase II flopFierceBiotech
KaloBios Pharma pulls plug on asthma drug, shares plungeReuters
KaloBios Shares Slide on Move to Stop Asthma Treatment StudyWall Street Journal
RTT News –San Francisco Business Times (blog)
all 30 news articles »

View full post on asthma – Google News

Posted on

Glaxo to Hike Stake in Theravance – Zacks.com


Proactive Investors USA & Canada

Glaxo to Hike Stake in Theravance
Zacks.com
The increased holding by the pharma major reflects its confidence in the Relovair program, under which the companies are looking to replace one of Glaxo's best selling drugs Advair by evaluating treatment options for asthma and chronic obstructive …
GlaxoSmithKline Boosts Stake In Theravance To 27%RTT News
GlaxoSmithKline to Increase Its Ownership in TheravanceMarketWatch (press release)
Glaxo Lifts Theravance StakeWall Street Journal
Triangle Business Journal
all 67 news articles »

View full post on asthma – Google News

Posted on

BSX’s Alair Receives Reimbursement – Zacks.com

BSX's Alair Receives Reimbursement
Zacks.com
Data from the Research in Severe Asthma (“RISA”) trial found that patients with severe refractory asthma, when treated with Alair BT system, experienced stability in lung function without clinical complications over a five-year period. …
St. Luke's Episcopal Hospital Offers Bronchial Thermoplasty Treating Severe …MarketWatch (press release)
CMS acknowledges clinical improvement linked with use of Alair Bronchial …News-Medical.net
Boston Scientific's Alair thermoplasty system wins CMS approvalZenopa

all 10 news articles »

View full post on asthma – Google News